Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Clin Pharmacokinet. 2013 Sep;52(9):751–762. doi: 10.1007/s40262-013-0069-2

Fig. 1. Combined effects of CYP3A5 polymorphism and ABCC2 haplotypes on dose-normalized tacrolimus concentration at pre-dose and 2-hour post-dose.

Fig. 1

Dose-normalized trough concentrations (A), 2-hour post-dose concentrations (B) and dose (C) of tacrolimus in stable kidney transplant recipients separated according to CYP3A5 polymorphism (CYP3A5 expressers or non-expressers) and ABCC2 haplotypes (MRP2 high activity group (H) or low activity group (L) + reference group (R)). The bars show the geometric means of dose-normalized tacrolimus concentration (A and B) and the median of tacrolimus dose (C) in each group. CYP, cytochrome P450; MRP2, multidrug resistance-associated protein 2.